Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2022-01-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
江苏泰和律师事务所关于受让池州东升药业有限公司部分股权并对其增资暨关联交易的的法律意见书-JCM
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a specific transaction involving the acquisition and capital increase of a company (池州东升药业有限公司) by 金陵药业股份有限公司. It details the legal qualifications of the parties, the legality of the equity, pricing basis, agreements, approvals, and procedures related to the transaction. The document is not a financial report, earnings release, or regulatory filing but a legal opinion on a corporate transaction. This type of document is best classified under Regulatory Filings (RNS) as it does not fit into other specific categories like M&A filings (which are more formal merger/tender offer filings), nor is it a proxy, audit, or capital update. The document is substantive and over 7,000 characters, so it is not a mere announcement or report publication notice.
2022-01-18 Chinese
金陵药业关于受让池州东升药业有限公司部分股权并对其增资暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the progress of its acquisition and capital increase in Chizhou Dongsheng Pharmaceutical Co., Ltd. It details the investment framework agreement, board resolutions, share transfer and capital increase agreements, payment methods, governance arrangements, and other related matters. The document is a formal public announcement of a corporate transaction involving equity transfer and capital increase, including related party transactions. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is a regulatory announcement about a capital and financing update related to the company's investment activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4976 characters) and content support this classification with high confidence.
2022-01-18 Chinese
金陵药业第八届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and decisions made by the board, including approval of related party transactions, land use rights auction participation, and convening a shareholders' meeting. The document is not a full report but a board meeting resolution announcement. It does not contain financial statements or detailed financial data. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-01-11 Chinese
金陵药业关于召开2022年第一次临时股东大会的通知
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting (临时股东大会) of Jinling Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be discussed, and proxy forms. The content focuses on the announcement and procedural details of a shareholders' meeting rather than the meeting materials or results themselves. There is no financial data or report content, nor is it a transcript or management report. It is not a report publication announcement since it contains substantive meeting details and instructions. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement sent to shareholders, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it relates to the voting process and shareholder meeting arrangements. Confidence is high due to the clear meeting and voting focus.
2022-01-11 Chinese
金陵药业股份有限公司独立董事关于公司第八届董事会第十六次会议审议的有关议案
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on the company's board meeting resolutions regarding the 2022 daily related party transactions. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on the independent directors' approval and opinion on specific board meeting agenda items, not on financial results or full reports. The document length is short (784 characters) and it is a formal opinion related to board meeting decisions. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or management matters. It is not an annual report, audit report, or earnings release, nor is it a regulatory filing or proxy solicitation. Therefore, the classification is MANG with high confidence.
2022-01-11 Chinese
金陵药业关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It details the amounts, dates, and returns of these financial products, along with risk disclosures and control measures. The document is relatively short (3167 characters) and focuses on a specific financing activity rather than comprehensive financial results or management discussion. It is not an annual or interim report, nor a call transcript or AGM material. It is a specific update on capital usage and investment activities, fitting the category of Capital/Financing Update (CAP).
2022-01-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.